display
Darmstadt / Mainz (dpa) - The Mainz-based company Biontech has also received approval under pharmaceutical law to manufacture corona vaccines at its plant in Marburg, Hesse.
This was announced by the Darmstadt Regional Council (RP) on Thursday.
Two weeks ago, Biontech had already received approval to operate its plant for the production of the agent - in this case the RP Gießen was responsible.
According to a spokesman for the Darmstadt authority, a further formal step is pending: In order to be able to market the vaccine produced in Marburg in the European Union, approval from the EU drug agency EMA is still required.
In the first half of 2021, 250 million doses of the vaccine are to be manufactured in Marburg by Biontech and its US partner Pfizer.
According to the company, the Mainz-based company is aiming for a total of 750 million cans for an annual production.
Three of the four necessary production steps should take place in Marburg.
Biontech had taken over the plant from the Swiss pharmaceutical company Novartis.
display
According to the last announcement, Biontech plans to start production in Marburg in February.
According to the company, it typically takes about four weeks between production and release of the controlled vaccine.
© dpa-infocom, dpa: 210128-99-211654 / 2